Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
Tempest Therapeutics
Tempest Therapeutics is a small Molecules for Immuno-Oncology.
Overview
Structured Data
Issues
Contributors
Activity
Access by API
Access by API
Is a
Organization
Company
Board of Directors
Christine Pellizzari
0
Mike Raab
0
Ronit Simantov
0
Tom Woiwode
0
Tom Dubensky
0
Geoff Nichol
0
CIK Number
1,544,227
0
Legal Name
Tempest Therapeutics, Inc.
0
Company Operating Status
Active
Country
United States
Crunchbase URL
crunchbase.com/organiz...apeutics
Email Address
careers@tempesttx.com
0
info@tempesttx.com
0
Full Address
7000 Shoreline Court Suite 275 South San Francisco, CA 94080, USA
0
Industry
Technology
Healthcare
Biotechnology
Biology
Engineering
Biomedical engineering
Immunotherapy
Oncology
Investors
Quan Capital
Eight Roads Ventures
Foresite Capital
Versant Ventures
F-Prime Capital Partners
Lilly Asia Ventures
IRS Number
451,472,564
0
Latest Funding Round Date
May 11, 2022
Latest Funding Round Amount (USD)
15,000,000
Latest Funding Type
Series B Round
LinkedIn URL
@company/tempesttx
Location
South San Francisco, California
0
San Francisco
NAICS Code
325,412
0
Number of Employees (Ranges)
11 – 50
Patents Assigned (Count)
3
Pitchbook URL
pitchbook.com/profiles.../54810-64
Place of Incorporation
Delaware
0
Previous Name
OvaScience, Inc.
0
Millendo Therapeutics, Inc.
0
SIC Code
2,834
0
Exchange
Nasdaq
0
Stock Symbol
TPST
0
Ticker Symbol
TPST
0
Total Funding Amount (USD)
85,000,000
Twitter URL
@tempest_tx
Official Website
tempesttx.com
Find more companies like Tempest Therapeutics
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE